Stockscreener 앱 받기
1.38
0.73%
0.010
NanoViricides Inc 주식(NNVC)의 최신 뉴스
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides - ACCESS Newswire
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - The Tennessean
Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com - Investing.com Nigeria
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Corsicana Daily Sun
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - FinancialContent
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Yahoo Finance
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - ACCESS Newswire
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
Book value per share of NanoViricides, Inc. – HAN:NV3P - TradingView
Cash flow from financing activities of NanoViricides, Inc. – HAN:NV3P - TradingView
NanoViricides, Inc. Balance Sheet – HAN:NV3P - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo! Finance Canada
NanoViricides, Inc. (NNVC) Files 10-K; NV-387 Enters Phase II Trials - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Q4 Earnings Snapshot - KHOU
NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary - TradingView
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - ACCESS Newswire
An Ebola trial in Congo is dosing patients with a drug that dissolves in the mouth. - Stock Titan
NanoViricides, Inc. Auditor Raises 'Going Concern' Doubt - www.marketscreener.com
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Inc. (NNVC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - ACCESS Newswire
NanoViricides, Inc. (NNVC) Starts Phase II Trial of NV-387 for Mpox - TradingView
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - Yahoo Finance
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides - Yahoo Finance
About 48% of confirmed Ebola cases in Congo have ended in death. NanoViricides' oral trial is set to start next week. - Stock Titan
Cash flow from financing activities of NanoViricides, Inc. – HAM:NV3P - TradingView
Operating cash flow per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Return on equity % of NanoViricides, Inc. – HAM:NV3P - TradingView
Gross margin % of NanoViricides, Inc. – HAM:NV3P - tradingview.com
CapEx per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Total debt per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz.co
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - Yahoo Finance
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Pre-Revenue DevelopmentGAAP Earnings Report - careplusvn.com
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NanoViricides (NNVC) Q2 2026 Earnings: Profit Per Share Surpasses Its Benchmark in the Latest Session; Closing Reaction: The Stock Loses 4.51% for the Current SessionProfit Guidance Range - vinanet.vn
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53% - careplusvn.com
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53%Subscription Growth Report - dars.gov.et
4.22%
자본화:
|
볼륨(24시간):